Novartis Makes Mayzent Case With More MS Data
Executive Summary
Presentations at ECTRIMS highlight the recently approved pill's effects on disability and cognition.
You may also be interested in...
BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed
Zeposia, one of three Celgene candidates central to last year’s merger with BMS, obtains US FDA approval in relapsing MS. BMS, however, will delay the launch due to the COVID-19 pandemic.
Novartis MS Drug Mayzent Gets Europe OK
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.
Novartis Upbeat As Ofatumumab Data Delivers In MS
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports